ISRG vs RTX: Which Is the Better Buy?

Side-by-side comparison of Intuitive Surgical, Inc. and RTX Corporation β€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-06-20.
Intuitive Surgical, Inc. Β· Healthcare
$406.78
+45.0% upside to fair value
Grade B High Quality
VS
RTX Corporation Β· Industrials
$185.60
-25.2% upside to fair value
Grade D
QuantHub Verdict
ISRG has more upside to fair value (+45.0%). RTX trades at a lower forward P/E (34.3x). These are model outputs β€” not personalized investment advice. See all research β†’
Valuation & Fundamentals
Metric ISRG RTX
Current Price $406.78 $185.60
Fair Value Estimate $589.83 $138.81
Upside to Fair Value +45.0% -25.2%
Market Cap $144.1B $249.9B
Forward P/E 48.6x 34.3x
EV / EBITDA 32.9x 18.3x
Price / Sales 13.6x 2.8x
Price / FCF 50.8x 29.9x
Revenue Growth YoY +23.0% +8.7%
Gross Margin 66.3% 20.2%
Operating Margin 30.5% 10.9%
Return on Equity 17.0% 11.2%
Dividend Yield 0% 0%
FCF Yield 1.97% 3.34%
Analyst Consensus Strong Buy Buy
Investment Thesis
ISRG β€” Intuitive Surgical, Inc.
Intuitive Surgical is a leading healthcare company specializing in robotic surgical systems, instruments, and accessories with a very wide competitive moat supported by over 80% global market share in installed systems and procedures. The company benefits from high recurring revenue streams driven by procedure volume and installed base utilization, with instruments and accessories generating $6.0…
RTX β€” RTX Corporation
RTX Corporation is a leading aerospace and defense company with a strong competitive moat driven by scale and an installed base in commercial aerospace via Pratt & Whitney and Collins Aerospace, and defense through Raytheon. The company benefits from a large multi-year backlog of approximately $270 billion supporting steady cash flow and mid-single-digit organic growth. Despite solid revenue grow…
Accumulation Zones
Metric ISRG RTX
Zone Low $442.37 $104.11
Zone High $501.36 $117.99
In Buy Zone? Yes No
← ISRG Research    RTX Research β†’    All Research